- Home
- INVE vs APLT Comparison
INVE vs APLT Comparison
Compare INVE & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | APLT |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 18.0M |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INVE | APLT |
|---|---|---|
| Price | $3.42 | $0.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $5.50 | $1.25 |
| AVG Volume (30 Days) | 37.6K | ★ 9.9M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,015,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | $11.82 | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $0.10 |
| 52 Week High | $4.07 | $1.50 |
Technical Indicators
Market Signals| Indicator | INVE | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 25.98 |
| Support Level | $3.40 | $0.10 |
| Resistance Level | $3.70 | $0.13 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 23.84 | 7.66 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.